Titanium Total Artificial Heart receives Breakthrough Designation from the FDA, as awarded to Bivacor.
**Current Status and Development Timeline of Bivacor's Titanium Total Artificial Heart**
The medical world is abuzz with the latest advancement in cardiac replacement technology, Bivacor's Titanium Total Artificial Heart (TAH). This innovative device, designed to completely replace the human heart, has recently received the Food and Drug Administration's (FDA) Breakthrough Device designation, signifying its potential to revolutionise the treatment of severe heart failure[1].
A significant milestone was achieved when an Australian patient was successfully implanted with the Bivacor TAH and subsequently discharged from the hospital. The patient remained at home with the device for 100 days before receiving a donor heart transplant[1]. The Bivacor TAH, made from titanium and approximately the size of an adult's fist, is the world's first implantable rotary blood pump[3][4].
The Bivacor TAH is a remarkable piece of engineering, boasting a simple design that employs just one moving part - a magnetically suspended rotor - to pump blood around the body. Unlike other designs of total artificial hearts, Bivacor has eliminated valves, flexing ventricle chambers, pumping diaphragms, and mechanical bearings[2].
The device is also designed to pump enough blood to support an adult man during exercise. A cord connects the device to either a portable power source or the mains, ensuring the patient's mobility is not compromised. Theoretically, the Bivacor TAH is suitable for longer-term use[5].
The development of the Bivacor TAH began at St. Vincent's Hospital, under the guidance of Dr. Daniel Timms. As of early 2025, significant clinical progress was made with the successful implantation and discharge of a patient[6]. The FDA breakthrough designation was granted as of June 2025, indicating a promising path toward regulatory approval[1].
Looking ahead, Bivacor is likely to continue advancing through clinical trials and regulatory processes to achieve full FDA approval. Other companies, such as Realheart, are also pursuing FDA approval for their total artificial hearts, aiming for both destination therapy and bridge to transplant applications[7].
In the United States, Bivacor tested the device in five patients in an early feasibility study, supporting them for up to one month while they waited for a donor heart[8]. The Food and Drug Administration designation could accelerate development of a device that kept a man alive for more than 100 days while he waited for a donor heart[9]. A man in Australia had the device for 105 days while he waited for a donor heart, making him the first person with the device to be discharged from the hospital while waiting for a heart transplant[10].
In summary, the Bivacor TAH represents a groundbreaking advancement in cardiac replacement technology, with significant milestones achieved in clinical use and regulatory recognition. The device's simple design, coupled with its potential for longer-term use, makes it a promising solution for patients with severe heart failure. As clinical trials and regulatory processes progress, we can look forward to the Bivacor TAH providing hope for those in need.
- The Food and Drug Administration (FDA) designated Bivacor's Titanium Total Artificial Heart (TAH) as a Breakthrough Device, signifying its potential to significantly improve treatment for severe heart failure.
- Advanced medical-condition analytics and news reports have highlighted the successful implantation of the Bivacor TAH in an Australian patient, who remained at home with the device for 100 days before receiving a donor heart transplant.
- As part of the medical-devices industry, Bivacor's TAH, a rotary blood pump made of titanium, is designed for longer-term use and is suitable for pumping enough blood to support an adult man during exercise.
- In the realm of science and health-and-wellness, the Bivacor TAH has eliminated valves, flexing ventricle chambers, pumping diaphragms, and mechanical bearings, resulting in a simple design with just one moving part.
- With the support of medtech and AI, Bivacor is continuing to progress through clinical trials and regulatory processes, aiming to achieve full FDA approval and offer hope for patients dealing with severe heart failure.
